Charles River

Charles River's Freiburg site is uniquely positioned to provide a comprehensive portfolio of non-GLP oncology services. Initially founded as Oncotest GmbH, the facilicy was acquired by Charles River in 2015.

They focuses on preclinical profiling of anticancer compounds utilizing a large collection of proprietary patient derived xenograft (PDX) models. Their outstanding market position is based on a unique integrated testing approach, which includes medium-high throughput in vitro assay systems complemented by extensive in vivo efficacy test capabilities. Charles River has established a unique collection of more than 500 PDX models throughout all major histotypes. Their PDX collection is very well characterized by molecular analyses as well as by sensitivity testing towards the respective standard of care compounds.

From their longstanding experience within the area of preclinical and translational oncology, they learned that there is an urgent need for primarily more predictive but also prognostic biomarkers. The aim of the LBI:AD addresses an urgent need of translational oncology, as biomarker research is lagging behind the advanced development of novel drugs. Therefore, the partnership on this project will help to reduce drug development failure rates and contribute to faster and more efficient development of novel innovative anti-cancer drugs. As a R&D focused CRO, Charles River is always in the process of optimizing their test systems with respect to clinical relevance. This includes the extended characterization of their PDX models with respect to their feasibility for biomarker identification and validation.